MXPA02008637A - Elemento de respuesta a factor de celulas t. - Google Patents

Elemento de respuesta a factor de celulas t.

Info

Publication number
MXPA02008637A
MXPA02008637A MXPA02008637A MXPA02008637A MXPA02008637A MX PA02008637 A MXPA02008637 A MX PA02008637A MX PA02008637 A MXPA02008637 A MX PA02008637A MX PA02008637 A MXPA02008637 A MX PA02008637A MX PA02008637 A MXPA02008637 A MX PA02008637A
Authority
MX
Mexico
Prior art keywords
constructs
tumour
responsive element
prodrug
selective
Prior art date
Application number
MXPA02008637A
Other languages
English (en)
Inventor
Christopher John Wrighton
Original Assignee
Ml Lab Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0005099A external-priority patent/GB0005099D0/en
Application filed by Ml Lab Plc filed Critical Ml Lab Plc
Publication of MXPA02008637A publication Critical patent/MXPA02008637A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describen elementos y construcciones de ADN utiles para obtener expresion de gen selectivo de tumor en tumores que tienen una via de ??-catenina/APC mutada; en particular, se describe el uso de estas construcciones para expresar genes que codifican proteinas terapeuticas en celulas de cancer colorrectal; las construcciones comprenden repeticiones multiples de un elemento de union a TCF operablemente enlazado a un promotor; por medio de dicha construccion, se puede lograr la expresion especifica de celulas tumorales de una enzima convertidota de profarmaco tal como nitmrreductasa; acoplada con la administracion sistemica de un profarmaco adecuado, tal como CB1954, se puede lograr la aniquilacion de dichas celulas tumorales.
MXPA02008637A 2000-03-02 2001-03-01 Elemento de respuesta a factor de celulas t. MXPA02008637A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0005099A GB0005099D0 (en) 2000-03-02 2000-03-02 TCF responsive elwment
US18746500P 2000-03-06 2000-03-06
PCT/GB2001/000856 WO2001064739A1 (en) 2000-03-02 2001-03-01 Tcf responsive element

Publications (1)

Publication Number Publication Date
MXPA02008637A true MXPA02008637A (es) 2004-09-06

Family

ID=26243787

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02008637A MXPA02008637A (es) 2000-03-02 2001-03-01 Elemento de respuesta a factor de celulas t.

Country Status (10)

Country Link
US (2) US6608037B2 (es)
EP (1) EP1268536A1 (es)
JP (1) JP2004500097A (es)
CN (1) CN1418224A (es)
AU (1) AU783128B2 (es)
CA (1) CA2401533A1 (es)
HK (1) HK1053845A1 (es)
IL (1) IL151500A0 (es)
MX (1) MXPA02008637A (es)
WO (1) WO2001064739A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500097A (ja) * 2000-03-02 2004-01-08 エムエル　ラボラトリーズ　ピーエルシー Ｔｃｆ応答性エレメント
JP2005504520A (ja) * 2001-06-13 2005-02-17 イースタン ヴァージニア メディカル スクール 治療用核酸の標的化発現の方法
NZ531413A (en) * 2001-08-21 2006-01-27 Innovata Plc Improved nitroreductase enzymes
GB0223696D0 (en) * 2002-10-14 2002-11-20 Ml Lab Plc Improved immunotherapy
WO2004070041A1 (en) * 2003-02-06 2004-08-19 Ml Laboratories Plc Vectors for expression of toxins
ES2341555T3 (es) * 2004-03-06 2010-06-22 Innovata Limited Terapia con profarmaco enzimatico para la reparacion de una articulacion.
GB0517957D0 (en) 2005-09-03 2005-10-12 Morvus Technology Ltd Method of combating infection
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
GB2442202A (en) 2006-09-30 2008-04-02 Morvus Technology Ltd Vermin poison
AU2008307643B9 (en) 2007-09-28 2014-04-17 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
WO2011125055A2 (en) * 2010-04-09 2011-10-13 Consorcio De Tecnologia E Innovacion En Salud S.A. Synthetic constructs for polynucleotide and protein expression
US10357577B2 (en) 2010-07-16 2019-07-23 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
ES2078521T3 (es) 1990-05-18 1995-12-16 Boehringer Ingelheim Int Nuevos conjugados de proteina-polication.
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
EP0638123B1 (en) * 1991-10-23 2006-12-27 Cancer Research Technology Limited Bacterial nitroreductase for the reduction of cb 1954 and analogues thereof to a cytotoxic form
CA2131620A1 (en) 1992-03-20 1993-09-30 Louis C. Smith A dna transporter system and method of use
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
FR2719316B1 (fr) 1994-04-28 1996-05-31 Idm Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
WO1996041606A2 (en) 1995-06-08 1996-12-27 Therexsys Limited Improved pharmaceutical compositions for gene therapy
WO1998007876A2 (en) 1996-08-16 1998-02-26 Medical Research Council Self-replicating episomal expression vectors conferring tissue-specific gene expression
JP2001512312A (ja) 1997-02-12 2001-08-21 コブラ セラピューティクス リミテッド 高効率トランスフェクションに関する組成物および方法
US5851775A (en) * 1997-03-20 1998-12-22 Johns Hopkins University β-catenin, Tcf-4, and APC interact to prevent cancer
EP0939122A1 (en) * 1998-02-27 1999-09-01 Universiteit Utrecht Mouse TCF-3 and TCF-4 and tumorigenesis related to WNT/Wingless signalling
AU6010699A (en) * 1998-09-25 2000-04-17 Universiteit Utrecht Apc-2
GB9906815D0 (en) 1999-03-24 1999-05-19 Isrec Anti-neoplastic viral agents
JP2004500097A (ja) * 2000-03-02 2004-01-08 エムエル　ラボラトリーズ　ピーエルシー Ｔｃｆ応答性エレメント

Also Published As

Publication number Publication date
CN1418224A (zh) 2003-05-14
JP2004500097A (ja) 2004-01-08
EP1268536A1 (en) 2003-01-02
US20040048293A1 (en) 2004-03-11
AU3755101A (en) 2001-09-12
HK1053845A1 (zh) 2003-11-07
AU783128B2 (en) 2005-09-29
CA2401533A1 (en) 2001-09-07
US7179646B2 (en) 2007-02-20
US20020165173A1 (en) 2002-11-07
IL151500A0 (en) 2003-04-10
WO2001064739A1 (en) 2001-09-07
US6608037B2 (en) 2003-08-19

Similar Documents

Publication Publication Date Title
MXPA02008637A (es) Elemento de respuesta a factor de celulas t.
AU2001265756A1 (en) Sleeping beauty, a transposon vector with a broad host range for the genetic transfprmation in vertebrates
IL148060A0 (en) Compositions and methods for improved cell culture
DE69935857D1 (de) Expression eukarotischer peptide in pflanzenplastiden
CY1111496T1 (el) Υβριδικος φορεας αδενοϊου/αλφαϊου για την αποτελεσματικη χορηγηση και εκφραση θεραπευτικων γονιδιων σε κυτταρα ογκου
IL132348A0 (en) Gene directed antibody-enzyme prodrug therapy
EP0364096A3 (en) Gene expression elements and the production of chimeric mouse-human antibodies
WO2002016583A3 (en) Constructs and their use in metabolic pathway engineering
MXPA04005266A (es) Inmunocitocinas con selectividad modulada.
EP1180932A4 (en) ADENOVIRUS WITH REINFORCED AND CONDITIONALLY REPLICATED INFECTIVE POWER, AND APPLICATIONS THEREOF
AU2003239823A1 (en) Optimization of transgene expression in mammalian cells
DE60026563D1 (de) Herstellung von polyketiden
IL135911A0 (en) Dna 19355 polypeptide, a tumor necrosis factor homolog
WO2003104276A3 (en) GENES AND POLYPEPTIDES RELATED TO HEPATOCELLULAR OR COLORECTAL CARCINOMA
WO2001062938A3 (en) Variant galactose oxidase, nucleic acid encoding same, and methods of using same
WO2023154968A3 (en) Dna constructs for improved t cell immunotherapy
Deng et al. Significant energy transfer from CpcG2-phycobilisomes to photosystem I in the cyanobacterium Synechococcus sp. PCC 7002 in the absence of ApcD-dependent state transitions
WO1999035245A3 (en) Methods for preparing and using immortalized human neuroendocrine cells
AU2002364302A1 (en) Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
AU2002349277A1 (en) Means for improving immune response
TR200101932T2 (tr) Gen terapisi-1
EP2484759A3 (en) Methods of refolding mammalian glycosyltransferases
EP0306107A3 (en) New yeast strains providing for an enhanced rate of the fermentation of sugars, a process to obtain such yeasts and the use of these yeats
EP1449431A4 (en) NON-HUMAN ANIMAL GENETICALLY MODIFIED SRGF ANIMAL
Sangiliyandi et al. A simple method for purification of thermostable levansucrase of Zymomonas mobilis from a recombinant Escherichia coli